The purpose of this study is to determine whether liposomal bupivacaine is effective in the management of pain following total joint arthroplasty, as compared to standard of care analgesia.
Liposomal bupivacaine (Exparel®) is a local anesthetic made up of liposomal encapsulated bupivacaine. It is designed to be injected at the time of surgery into the local soft tissues. Because of its unique liposomal delivery system, Liposomal bupivacaine (Exparel®) has been shown to provide up to 96 hours of pain relief following surgeries. This makes it an attractive option in total joint arthroplasty patients. Combined with the proven efficacy of regional anesthesia, intraoperative liposomal bupivacaine (Exparel®) may provide extended pain relief following total joint arthroplasty. This has the potential to avoid the need for opioid medications. With better pain control, medication side effects can be avoided and patient's length of stay in the hospital can be shortened.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
211
OhioHealth Riverside Methodist Hospital
Columbus, Ohio, United States
Length of Stay in Hospital (Days)
Time frame: Participants were followed for the duration of hospital stay, an expected average of 3 days
Time to Post-operative Rescue Opioids (Hours)
Time frame: Immediately following discharge from operating room until the participant was discharged from the hospital, an expected average of 3 days
Readmission or Emergency Department (ED) Visit Due to Pain Control Within 30 Days
Time frame: Date of discharge through 30 days following discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.